Jubilant Lifesciences gains as company calls off deal with Cyclopharm

NEW DELHI: Shares of Jubilant Life Sciences ended 2.32 per cent higher on Thursday after the company its wholly-owned subsidiary and Australia-based Cyclopharm mutually called off their previously announced term sheet for exclusive commercial rights for Technegas in the US market.

Reacting to the development, the scrip gained 4.23 per cent to hit a high of Rs 394.80 on the BSE. The stock has slumped 6 per cent in the year so far.